The complaint alleges that ADMA Biologics violated the Securities Exchange Act by failing to disclose a significant related-party transaction. Furthermore, the lawsuit claims the company artificially inflated its sales performance through channel stuffing—a practice of pressuring distributors to purchase more inventory than they can sell to boost quarterly figures. These actions allegedly resulted in false and misleading public statements throughout the specified class period.
The DJS Law Group is spearheading the effort to appoint a lead plaintiff, with an August 10, 2026, deadline for interested shareholders. While lead plaintiff status offers a role in the litigation process, firm representatives emphasize that shareholders are not required to hold this position to participate in any potential financial recovery.
Comments (0)
No comments yet. Be the first!